A Study of Xolair in Peanut-Allergic Subjects Previously Enrolled in Study Q2788g

Record History

See every version on ClinicalTrials.gov ↗

1. Minor May 6, 2026 Enrollment target: 10 to 11

   • Primary completion date: Jun 2008 to Jun 28, 2008
   • Study completion date: Jun 28, 2008
   • Secondary endpoints: details revised at 1 of 3 entries

   v7
2. Notable Nov 12, 2009 Results first posted: Dec 15, 2009v6 Show 5 more changesShow less

   • Enrollment target: estimated 25 to confirmed 10
   • Primary completion date: Jun 2008
   • Study completion date: Jun 2008 to not stated
   • Secondary endpoints: 4 to 3
   • Primary endpoint revised
3. Minor Dec 5, 2008 Trial status: Active, Not Recruiting to Completed

   • Study completion date changed from estimate of Nov 2008 to Jun 2008

   v5
4. Minor Dec 22, 2007 Study completion date: Nov 2008v4 Show 5 more changesShow less

   • Start date: Oct 2006 to Nov 2006
   • Interventions: Xolair (omalizumab) (Drug) to omalizumab (Drug)
   • Eligibility criteria revised
   • Secondary endpoints revised (4)
   • Study arms: 0 to 1
5. Notable Dec 3, 2007 Primary endpoint revisedv3 Show 4 more changesShow less

   • Trial status: Recruiting to Active, Not Recruiting
   • Study sites: 1 to 0
   • Eligibility criteria revised
   • Secondary endpoints revised (4)
6. Notable Jan 22, 2007 Trial status: Not Yet Recruiting to Recruiting

   • Study sites: 0 to 1

   v2
7. Sep 26, 2006 Study First Submitted

• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.